Market Insights Health Medical Technology

In Vitro Diagnostics - United States

United States

The projected revenue in the In Vitro Diagnostics market market in the United States is estimated to be €27.92bn in 2024.
This market is expected to experience an annual growth rate of 2.55% from 2024 to 2029, resulting in a market volume of €31.66bn by 2029.
It is worth noting that the in the United States is anticipated to generate the highest revenue in global comparison, with €27.92bn in 2024.
The United States is experiencing a surge in demand for in vitro diagnostics, driven by an aging population and increasing prevalence of chronic diseases.

Key regions: China, France, Japan, Netherlands, Italy

Mercado

Región

Comparación de regiones

Moneda

Analyst Opinion

The In Vitro Diagnostics market in the United States is experiencing significant growth and development.

Customer preferences: Customers in the United States have shown a strong preference for advanced and innovative diagnostic technologies. They are increasingly seeking accurate and rapid diagnostic solutions that can provide early detection of diseases and conditions. This preference is driven by the growing awareness among the population about the importance of early diagnosis and the potential benefits it can bring in terms of treatment outcomes and cost savings. Additionally, customers in the United States value convenience and accessibility, and are more likely to choose diagnostic tests that can be easily performed at home or in point-of-care settings.

Trends in the market: One major trend in the In Vitro Diagnostics market in the United States is the increasing adoption of molecular diagnostics. This technology allows for the detection and analysis of genetic markers and biomarkers, enabling more precise and personalized diagnostics. The growing understanding of the genetic basis of diseases, coupled with advancements in molecular diagnostic techniques, has led to the development of targeted therapies and personalized medicine. As a result, there is a growing demand for molecular diagnostic tests in the United States. Another trend in the market is the rise of digital diagnostics. With the increasing use of smartphones and wearable devices, there is a growing interest in digital health solutions that can provide real-time monitoring and analysis of health data. Digital diagnostics offer the potential for remote monitoring, early detection of diseases, and improved patient outcomes. The United States has a highly developed healthcare infrastructure and a large market for digital health solutions, which is driving the adoption of digital diagnostics in the country.

Local special circumstances: The United States has a well-established healthcare system with a strong emphasis on preventive care and early detection of diseases. The country has a high healthcare expenditure and a large population, which creates a favorable market environment for In Vitro Diagnostics. Additionally, the United States has a highly competitive market with a large number of players, including multinational corporations and local manufacturers. This competition drives innovation and encourages the development of new and improved diagnostic technologies.

Underlying macroeconomic factors: The United States has a strong economy with high disposable income levels, which allows for greater spending on healthcare and diagnostics. The country also has a well-developed healthcare insurance system, which provides coverage for a significant portion of the population. This ensures that a large number of individuals have access to diagnostic tests and encourages the demand for In Vitro Diagnostics. Furthermore, the United States has a robust regulatory framework for medical devices, including In Vitro Diagnostics, which ensures the safety and effectiveness of these products. This regulatory environment provides confidence to customers and promotes the growth of the market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on medical devices and IVD revenues allocated to the country where the money is spent at manufacturer price levels excluding VAT.

Modeling approach / Market size:

Modeling employs a top-down approach with a bottom-up validation, using financial information of the key players by market. Market sizes are determined by a top-down approach, based on a specific rationale for each market market and allocated to the covered countries according to the global market shares. As a basis for evaluating markets, we use relevant key market indicators and data from country-specific associations, such as healthcare expenditure per capita, health risk factors, healthcare system, and regulations concerning medical products. Next, we use further relevant key market indicators and data from country-specific associations, such as healthcare expenditure per capita, health risk factors, healthcare payer system, and regulations concerning medical products. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level.